As the next round of states debate marijuana legalization, they would do well to contemplate allowing state governments to control the wholesale prices and linking the price of cannabis to its potency.
Illicitly sourced synthetic opioids, such as fentanyl, are involved in most of today's overdose deaths. Though most of these substances appear to come from China, many dimensions of this problem are unclear. Understanding the shifting supply of opioids is critical to addressing the overdose crisis.
Abundant supply of opioids was one of the major causes of the opioid crisis. Broader supply-side policies that consider the full market, if coupled with effective treatment, are likely to be effective and resistant to substitution effects.
The association between medical marijuana and lower levels of opioid overdose deaths—identified previously in several studies—is more complex than previously described. It appears to be changing as both medical marijuana laws and the opioid crisis evolve.
Approximately 18.5 million Americans aged 12 or older reported buying marijuana in the past year; they were more likely to be male, report using marijuana for a greater number of days, and report dependence on marijuana.
The EU Drugs Strategy takes a balanced approach to reduce drug demand, supply, and harm. All EU member states have a national drugs strategy, and most are aligned with the EU's. Having a coordinated voice on drug policy is valuable but is the strategy working?
In this study, we examine the Drug Market Intervention (DMI) program, which was replicated dozens of times based on early successes. This study represents the first effectiveness trial of DMI by following a cohort of sites attempting to implement it.
Prohibitions on producing, distributing, and selling cannabis are loosening in various jurisdictions around the world, but the evidence base for assessing changes in cannabis supply laws remains weak..
The study investigates mechanisms thought to support immediate and sustained change after a DMI by analyzing qualitative data collected in community focus groups conducted at three-, six-, and 15-months following a DMI across three different sites.
In this June 9th, 2017 congressional briefing, Beau Kilmer, codirector of the RAND Drug Policy Research Center, provides an overview of recent changes in marijuana policies as well as options for the federal government.
The report sets out the findings of an evaluation that assesses the degree of implementation of the EU Drugs Strategy 2013-2020 and the Action Plan 2013-2016 in all 28 EU Member States in terms of outputs and, where possible, impacts.
Data lags and the elimination of the ADAM program complicate estimates of U.S. cocaine consumption. New users who haven't yet developed cocaine dependence are also a factor. It may be prudent to start planning for an increase in heavy use even before all of the evidence is in.
The new administration has at least six options for addressing marijuana. These are not mutually exclusive, and each comes with tradeoffs. All six are compatible with a federal approach that encourages discussions about prohibition and its alternatives.